March 17, 2021

Rochelle Walensky, MD, MPH
Director, Centers for Disease Control and Prevention
1600 Clifton Road
Atlanta, GA 30329

Dear Director Walensky:

On behalf of the Cystic Fibrosis Foundation, the International Society for Heart and Lung Transplantation, and the below signed members of the Cystic Fibrosis Lung Transplant Consortium, we write in response to the Centers for Disease Control and Prevention (CDC) Interim Public Health Recommendations for Fully Vaccinated People.¹

We urge the CDC to provide further clarity, specificity, and increased prominence in recommendations for vaccinated individuals who are immunocompromised. We appreciate the importance of this guidance in providing much-needed direction to those who are fully vaccinated on what public health measures can be eased at this time. However, we are deeply concerned that the guidance does not clearly reflect the unique circumstances of those who are immunocompromised and their greater risk of not mounting an adequate immune response to vaccination, including those who have received a solid organ transplant.

**Fully vaccinated individuals with immunocompromising conditions need clear guidance on the importance of continuing protective behaviors**

We appreciate that the CDC has included a recommendation that fully vaccinated individuals with immunocompromising conditions discuss their individual circumstances with their care provider. However, the statement provided in the CDC’s recommendations fails to clearly and adequately reflect the importance of continued protective behaviors for these individuals in the absence of widespread COVID-19 vaccination and herd immunity. We are additionally concerned that this limited acknowledgement that individual circumstances may impact recommendations about public health measures is not given appropriate prominence in the CDC’s recent guidance.

COVID-19 represents a serious threat for this population. Over 260 people with CF received transplants in 2019, the majority of which were lung transplants.² Results from a published global analysis of 181 COVID-19 cases among people with CF indicate that individuals who are post-lung transplantation may be at risk of severe outcomes including death.³ As such, COVID-19 vaccines are an important addition to

---

the protective measures needed to reduce the risk posed by the virus for transplant recipients and other immunocompromised individuals.

We know that individuals who are immunocompromised, including those who have received a solid organ transplant, do not tend to mount as robust a response to vaccines compared to those without such conditions. For example, the standard dose influenza vaccine elicits less of an immune response in transplant recipients compared to others. Data on immunogenicity of COVID-19 vaccines in immunocompromised individuals is still limited at this time. However, a recently published study of 436 transplant recipients found that the immune response following the first dose of an mRNA COVID-19 vaccine appears to be significantly dampened compared to those who participated in clinical trials for the FDA-authorized COVID-19 vaccines. Of note, individuals receiving antimetabolite maintenance immunosuppression therapy, which is commonly used in lung transplantation, were even less likely to mount an antibody response.

We believe it is necessary for the CDC to urge caution at this time for solid organ transplant recipients on immunosuppression given that currently available data and experience with other vaccines indicates that COVID-19 vaccines may not provide the same level of protection for these individuals. Clear guidance for immunocompromised patients should be featured prominently to ensure that information on appropriate protective behaviors reaches this vulnerable population.

*****

Once again, we urge the CDC to further clarify, specify, and increase the prominence of recommendations for individuals with immunocompromising conditions. We thank you for your attention and consideration of transplant recipients as you tackle these difficult issues around evolving public health recommendations. We are happy to serve as a resource and stand ready to work alongside the CDC in this endeavor.

Sincerely,

Mary Dwight
Chief Policy and Advocacy Officer
Senior Vice President of Policy and Advocacy
Cystic Fibrosis Foundation

Albert Faro, MD
Vice President, Clinical Affairs
Cystic Fibrosis Foundation

Greg Schultz, CAE
Chief Executive Officer
International Society for Heart and Lung Transplantation

---


CF Lung Transplant Consortium Members

Luke Benvenuto, MD
Assistant Professor of Medicine
Center for Advanced Lung Disease and Transplantation
Columbia University Medical Center

Jason Christie, MD, MS
Chief, Pulmonary, Allergy and Critical Care Division
Penn Medicine

Gundeep Dhillon, MD, MPH
Medical Director, Heart-Lung & Lung Transplantation Program
Stanford HealthCare

Daniel Dilling, MD
Medical Director, Lung Transplantation
Loyola University Medical Center

Courtney Frankel, PT, MS
Research Program Leader
Duke University Medical Center

Ramsey Hachem, MD
Professor of Medicine, Lung Transplant Program Medical Director
Washington University School of Medicine

Matthew Hartwig, MD, MHS
Associate Professor of Surgery
Program Director, Minimally Invasive Thoracic Surgery Fellowship
Division of Thoracic Surgery
Duke University Health System

Steven Hays, MD
Medical Director, Lung Transplant Program
University of California San Francisco

Erika Lease, MD
Medical Director, Lung Transplant Program
University of Washington Medical Center

Christian Merlo, MD, MPH
Associate Professor of Medicine and Epidemiology, Division of Pulmonary and Critical Care
Johns Hopkins University School of Medicine

Isabel Neuringer, MD
Associate Medical Director, Lung Transplant Program and Adult Cystic Fibrosis Center
Massachusetts General Hospital
Jagadish Patil, MD
Assistant Professor of Medicine
Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine
University of Minnesota

Joe Pilewski, MD
Associate Chief, Division of Pulmonary, Allergy & Critical Care Medicine
University of Pittsburgh Medical Center

Kathleen Ramos, MD, MSc
Assistant Professor of Pulmonary, Critical Care, and Sleep Medicine
University of Washington, Seattle

John M. Reynolds, M.D.
Medical Director, Lung Transplant Program
Duke University

Pali Shah, MD
Medical Director, Lung Transplant
Johns Hopkins University School of Medicine

Laurie Snyder, MD, MHS
Associate Professor of Medicine, Pulmonary Allergy and Critical Care Medicine
Duke University School of Medicine

Stuart Sweet, MD, PhD
Professor of Pediatrics, Division of Allergy, Immunology and Pulmonary Medicine
Medical Director, Pediatric Lung Transplant Program
Washington University School of Medicine in St. Louis

Fanny Vlahos
Cystic Fibrosis Lung Transplant Consortium Patient Representative

Stephen Weigt, MD
Associate Professor of Medicine, Pulmonary and Critical Care
UCLA Medical Center

CC: Stephanie Bialek, MD, MPH, Director, Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, CDC

Capt. Amanda Cohn, MD, Chief Medical Officer (Acting), Office of Vaccine Policy, Preparedness, and Global Health, Office of the Director, National Center for Immunization and Respiratory Diseases, CDC